KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Assets: 2015-2025

Historic Other Non-Current Assets for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $24.3 million.

  • CRISPR Therapeutics AG's Other Non-Current Assets rose 111.01% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 111.01%. This contributed to the annual value of $15.8 million for FY2024, which is 36.56% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Other Non-Current Assets of $24.3 million as of Q3 2025, which was down 4.57% from $25.5 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Non-Current Assets peaked at $25.5 million during Q2 2025, and registered a low of $11.5 million during Q1 2024.
  • In the last 3 years, CRISPR Therapeutics AG's Other Non-Current Assets had a median value of $11.8 million in 2023 and averaged $15.3 million.
  • In the last 5 years, CRISPR Therapeutics AG's Other Non-Current Assets soared by 234.14% in 2021 and then slumped by 32.91% in 2022.
  • CRISPR Therapeutics AG's Other Non-Current Assets (Quarterly) stood at $16.9 million in 2021, then tumbled by 31.21% to $11.6 million in 2022, then decreased by 0.38% to $11.6 million in 2023, then spiked by 36.56% to $15.8 million in 2024, then surged by 111.01% to $24.3 million in 2025.
  • Its Other Non-Current Assets was $24.3 million in Q3 2025, compared to $25.5 million in Q2 2025 and $20.8 million in Q1 2025.